Reata Pharmaceuticals Accounts Payable

Reata Pharmaceuticals (RETA) currently reports a accounts payable of $20M as of June 2023. That compares with $7.8M in the prior-year period — up 156.1% year over year. Use the charts on this page to explore Reata Pharmaceuticals's accounts payable history and peer comparisons.

Reata Pharmaceuticals's accounts payable increased from $7.8M to $20M — a 156.1% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reata Pharmaceuticals reported $20M in accounts payable as of June 2023. That compares with $7.8M in the prior-year period — up 156.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.